Clinical Trial Results: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating delamanid with an optimized background regimen for pediatric multidrug-resistant tuberculosis, including subgroups with and without H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Tuberculosis

Drugs mentioned

• Delamanid (delamanid)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tuberculosis, HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-25